Asset Analysis · November 2025
In the field of US biotechnology, I found three companies that, in my opinion, combine tangible progress, sound science, and accessible catalysts: Iovance Biotherapeutics ($IOVA), a pioneer in TIL cell therapies for solid tumors; Gain Therapeutics ($GANX), with its Magellan™ computational platform for neurodegenerative diseases; and Gossamer Bio ($GOSS), with inhaled seralutinib for pulmonary hypertension.
Comparative Summary
| Ticker | Company | Current price | Target price | Estimated upside |
|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics | $2,30 | $10,00 | +334,78% |
| GANX | Gain Therapeutics | $2,36 | $12,00 | +408,47% |
| GOSS | Gossamer Bio | $2,50 | $15,00 | +500,00% |
Target prices are based on market potential, revenue projections, and regulatory approvals, with upward adjustments in the event of successful launches. They are subject to the risks inherent in the clinical-phase biotechnology sector.
The company
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company that develops cell therapies based on tumor-infiltrating lymphocytes (TILs) autologous therapies, focused on the treatment of advanced solid tumors such as melanoma, cervical cancer, and NSCLC. In simple terms: immune system cells are extracted from the tumor, multiplied and strengthened in the laboratory, and reintroduced into the patient’s body so that they can recognize and destroy cancer cells.
Founded in 2007 and headquartered in San Carlos, California, it operates in a initial growth phase following the approval of its main therapy Amtagvi® (lifileucel) by the FDA in 2024, with revenue of ~68 M USD in Q3 2025 and projections for growth to more than 70 authorized treatment centers (ATC).
Fundamental analysis
| Metrics | IOVA | Comparison | Comment |
|---|---|---|---|
| Market Capitalization | $913M | Pairs $1,100M · Sector $81.8M | Mid-to-small-cap company in the process of going public |
| Revenue (Q3) | ~$68M / $250M TTM | Pairs +10.81 TP3T YoY | +1,751 TP3T YoY thanks to Amtagvi® |
| PER | –2,3x | Pairs –9.3x · Sector –0.6x | TTM Net Losses 1Q4T3: 397.6M · Better than peers |
| P.S. | 3,6x | Pairs 8.1x · Sector 3.3x | A Prudent Assessment Amid Growth Uncertainty |
| Cash | $524.2M | — | Runway of 12–18 months without significant dilutions |
| EBITDA | –$411.3M | — | Gross margin: –158.81 TP3T, typical for early-stage cell therapies |
| Beta | 0,85 | — | Lower systemic volatility · conservative investor interest |
| Short float | 28,57% | Short ratio 5.27 | Potential price surge if NSCLC data are confirmed |
IOVA reports revenue growth of +1,751 TP3T year-over-year, well above the 10.8% for peers and the 6.2% for the sector. Its balance sheet shows 524.2 million USD in cash and total assets of 904.9 million USD. The short float of 28,57% (ratio of 5.27 days) and the increase since 22% in September raise the possibility of a accelerated short squeeze given a positive catalyst. Analysts estimate the stock is undervalued at 204.30%, with a consensus projection of 100-200% upside over the next 12-18 months.
IOVA Catalysts
Published data: P/E ratio of 25.61 for Q3 (10 of 39 patients, including 2 complete responses), mDOR not yet reached (>14 months). The FDA issued positive feedback for a sBLA in 2026 and commercial launch in the second half of 2027. A medical conference in 2026 will confirm its durability and safety.
Phase 2 data reading, objective of ORR of 25% (vs. historical rate <15%). A positive result allows for an sBLA and access to the The gynecological market is estimated to be worth more than 1,000 M USD at peak sales. It enhances the versatility of Amtagvi® beyond melanoma.
Phase 1/2 Update with an Improved Version of Lifileucel in PD-1 Inhibitor-Resistant Melanoma. Potential to Demonstrate clinical superiority and establish a leading position in first-line treatment and combination therapies with pembrolizumab.
Presentation to the EMA In progress, potential approval in 2026. Projected gross margins >50% in Q4 2025 Thanks to the iCTC. Projections of profitability in Q4 2026 even without international revenue.
IOVA Scenarios
Interactive tool
Activate the catalysts to calculate the target price range. The NSCLC catalyst (IOV-LUN-202) has the greatest potential impact given the size of the market.
IOVA Technical Analysis
Source: IOVA TF 1D · TradingView · Created by Diego García del Río · November 2025
The company
Gain Therapeutics is a clinical-stage biotechnology company focused on precision therapies for neurodegenerative diseases, with its computing platform Magellan™. as a key technological differentiator. Magellan™ identifies «hidden» allosteric sites» in proteins—binding pockets other than the traditional active site—allowing for the design of small molecules that regulate protein function more selectively and with a better safety profile than conventional drugs.
Its main asset is GT-02287, currently in Phase 1b for Parkinson-GBA (the most common genetic form of Parkinson's disease, associated with mutations in the GBA1 gene). The company operates with limited liquidity, but enough to cover upcoming catalysts, and maintains a high speculative potential in light of the Phase 1b data and the possible transition to Phase 2 in 2026.
GANX Catalysts
The release of Phase 1b safety, tolerability, and efficacy data is the main short-term catalyst. A favorable profile would pave the way for a Phase 2 in 2026, which would represent a significant increase in market capitalization. Parkinson-GBA affects between 5 and 15% of all Parkinson's patients, accounting for a a market worth several billion dollars with no approved disease-modifying treatment.
Magellan™ is not just a tool for Parkinson's disease: it can be applied to any protein with identifiable allosteric sites. GANX's preclinical pipeline includes additional programs targeting other lysosomal storage disorders and tauopathies. The platform value It could attract industrial partnerships or strategic alliances.
The scarcity of disease-modifying therapies for Parkinson's disease, combined with the pharmaceutical industry's interest in small-molecule compounds for neurodegenerative disorders (which are logistically more manageable than gene or cell therapies), positions GANX as a potential acquisition target as clinical data progresses.
GANX Stages
Interactive tool
Without positive Phase 1b data, GANX's investment thesis lacks a basis for short-term appreciation.
The company
Gossamer Bio is an advanced-stage clinical-phase biopharmaceutical company focused on rare lung diseaseswith seralutinib as the primary active ingredient. Seralutinib is a PDGFR/KIT/CSF1R inhibitor administered by direct inhalation — a targeted route of administration that aims to maximize pulmonary concentration and minimize systemic effects, a key advantage over systemic oral inhibitors in PAH.
It is being tested in two Phase 3 studies: PROSERA for pulmonary arterial hypertension (PAH) and SERANATA for pulmonary hypertension associated with interstitial lung disease (PH-ILD), with key data expected in 2025-2026. The PAH market is valued at several billion dollars, with a patient population that requires combination therapies.
GOSS Catalysts
The PROSERA study in PAH is the most significant catalyst for GOSS. A positive result for the primary endpoint (reduction in pulmonary vascular resistance or improvement in the 6-minute walk test) would enable a submission to the FDA and potentially approval, in a market with More than 20 approved drugs, but a need for additional combinations.
PH-ILD is a condition characterized by greatest unmet need than PAH alone, which has more limited treatment options. A positive result in SERANATA would significantly expand the potential market for seralutinib, positioning GOSS as the dominant player in an indication where no drug has established approval.
Most of the available PDGFR inhibitors are oral and systemic, with toxicity profiles that limit their use in PAHs. The inhaled administration of seralutinib It allows for high local concentrations with lower systemic exposure, reducing adverse effects and improving the therapeutic index. This is GOSS’s strongest point of differentiation from potential competitors.
GOSS Scenarios
Interactive tool
GOSS's thesis is binary: it relies primarily on clinical data from PROSERA and SERANATA.
Frequently Asked Questions
All three are biotech companies in the clinical stage focused on indications with high unmet medical needs and with key milestones coming up in 2025–2026. IOVA operates in immuno-oncology with TIL therapies; GANX in neurology with allosteric molecules for Parkinson’s disease and GBA; and GOSS in pulmonology with seralutinib for PAH and PH-ILD.
Amtagvi® (lifileucel) is Iovance’s TIL therapy, approved by the FDA in 2024 for advanced metastatic melanoma. It is the first and only approved TIL cell therapy for solid tumors, and differs from CAR-T therapies in that it uses cells from the patient’s own tumor.
Magellan™ is Gain Therapeutics« proprietary computational platform that identifies »hidden” allosteric sites in proteins, enabling the design of small molecules that regulate protein function more selectively. Its main application is GT-02287 for Parkinson’s disease caused by GBA mutations, currently in Phase 1b.
Seralutinib is an inhaled PDGFR/KIT/CSF1R inhibitor; this unique route of administration maximizes pulmonary concentration and minimizes systemic effects. It is currently being evaluated in two Phase 3 studies: PROSERA (PAH) and SERANATA (PH-ILD), with key data expected in 2025–2026.
Markets by Diego is the financial analysis platform of Diego García del Río, a Spanish economist and independent private investor, and founder of Hill Valley Consulting. He publishes asset analyses, macroeconomic reports, and strategies involving options and leveraged ETFs, along with tracking of actual trades in international markets.
More analysis by Diego García del Río
Spanish 
English 
German 
French